Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | cytochrome P450 reductase, putative | 0.0192 | 0.8717 | 0.8717 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0083 | 0.3033 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0076 | 0.2693 | 0.2693 |
Leishmania major | hypothetical protein, conserved | 0.0083 | 0.3033 | 0.3033 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.2693 | 0.2693 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0083 | 0.3033 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0134 | 0.5684 | 0.5684 |
Chlamydia trachomatis | sulfite reductase | 0.0134 | 0.5684 | 1 |
Trypanosoma cruzi | Flavodoxin/Radical SAM superfamily/Wyosine base formation, putative | 0.0083 | 0.3033 | 0.3033 |
Trypanosoma cruzi | NADPH--cytochrome P450 reductase, putative | 0.0083 | 0.3033 | 0.3033 |
Plasmodium vivax | hypothetical protein, conserved | 0.0083 | 0.3033 | 0.3033 |
Schistosoma mansoni | diflavin oxidoreductase | 0.0108 | 0.4316 | 0.4316 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.2693 | 0.2693 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0192 | 0.8717 | 1 |
Brugia malayi | flavodoxin family protein | 0.0083 | 0.3033 | 0.3033 |
Treponema pallidum | flavodoxin | 0.0083 | 0.3033 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.2693 | 0.2693 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0083 | 0.3033 | 0.5 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 0.2693 | 0.2693 |
Brugia malayi | MH2 domain containing protein | 0.0144 | 0.6209 | 0.6209 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0083 | 0.3033 | 0.5 |
Trypanosoma brucei | S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase, putative | 0.0083 | 0.3033 | 0.3033 |
Echinococcus multilocularis | methionine synthase reductase | 0.0134 | 0.5684 | 0.5684 |
Trypanosoma cruzi | Flavodoxin/Radical SAM superfamily/Wyosine base formation, putative | 0.0083 | 0.3033 | 0.3033 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 0.6209 | 0.6209 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0108 | 0.4316 | 1 |
Plasmodium vivax | flavodoxin domain containing protein | 0.0192 | 0.8717 | 0.8717 |
Giardia lamblia | Hypothetical protein | 0.0192 | 0.8717 | 1 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 0.6209 | 0.6209 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 0.2693 | 0.2693 |
Trichomonas vaginalis | NADPH fad oxidoreductase, putative | 0.0192 | 0.8717 | 0.8159 |
Entamoeba histolytica | type A flavoprotein, putative | 0.0083 | 0.3033 | 0.5 |
Plasmodium falciparum | S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase, putative | 0.0083 | 0.3033 | 0.3033 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 0.2693 | 0.2693 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 0.2693 | 0.2693 |
Echinococcus granulosus | methionine synthase reductase | 0.0134 | 0.5684 | 0.5684 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.2693 | 0.2693 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0134 | 0.5684 | 0.5684 |
Plasmodium falciparum | NADPH--cytochrome P450 reductase, putative | 0.0083 | 0.3033 | 0.3033 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0109 | 0.4402 | 0.4402 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 0.2693 | 0.2693 |
Brugia malayi | RNA binding protein | 0.0076 | 0.2693 | 0.2693 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.2693 | 0.2693 |
Brugia malayi | FAD binding domain containing protein | 0.0134 | 0.5684 | 0.5684 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 0.2693 | 0.2693 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0108 | 0.4316 | 1 |
Loa Loa (eye worm) | flavodoxin family protein | 0.0083 | 0.3033 | 0.3033 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 7.0795 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent). (Class of assay: confirmatory) [Related pubchem assays: 2158 (Confirmation qHTS Assay for Inhibitors of Cruzain), 2249 (Probe Development Summary of Promiscuous Inhibitors (Artifacts) of Cruzain), 2161 (qHTS Assay for Inhibitors of Papain: Counterscreen for Cruzain Assay), 1478 (qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent))] | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.